NCT06780839 is a Phase 2 clinical trial of Ensartinib in NSCLC, Stage I, II, IIIA, IIIB, sponsored by Peking University Cancer Hospital & Institute.

Who is sponsoring NCT06780839?

NCT06780839 is sponsored by Peking University Cancer Hospital & Institute.

What drugs are being tested in NCT06780839?

Interventions in NCT06780839: Ensartinib.

What condition does NCT06780839 study?

NCT06780839 studies NSCLC, Stage I, II, IIIA, IIIB.

Is NCT06780839 still recruiting?

NCT06780839 is currently not yet recruiting. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT06780839

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Not yet recruiting Phase 2 Last updated 17 January 2025

What this trial tests

Phase 2 trial testing Ensartinib in NSCLC, Stage I, II, IIIA, IIIB in 70 participants. Not yet recruiting.

Timeline

15 January 2025

Primary endpoint
15 January 2029

15 January 2030

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	15 January 2025
Primary completion	15 January 2029
Estimated completion	15 January 2030
Sites	1 location across China

Drugs / interventions tested

Ensartinib (ENSARTINIB) — full drug profile →

Conditions studied

NSCLC, Stage I, II, IIIA, IIIB — all drugs for NSCLC, Stage I, II, IIIA, IIIB →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

18 and older, any sex, with NSCLC, Stage I, II, IIIA, IIIB. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the efficacy and safety of ensartinib on adjuvant therapy guided by MRD in IA3-IIIB (T3N2) stage ALK-positive non-small cell lung cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives.
Koutoukoglou P, Mountzios G. · · 2026 · PMID 41681965 · DOI 10.3390/cancers18030493

Verify or expand the search:

Other trials of Ensartinib

Trials testing the same drug.

NCT07448116 — Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. · Phase 1, PHASE2 · recruiting
NCT06762327 — Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer · Phase 2 · not yet recruiting
NCT06785584 — Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Pos · Phase 4 · not yet recruiting
NCT06779539 — Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06563999 — Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · Phase 2 · recruiting

Other Peking University Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06780839 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06780839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing